Kestra Medical (Nasdaq: KMTS) boosts Q3 sales 63% and raises 2026 guidance
Rhea-AI Filing Summary
Kestra Medical Technologies reported strong growth for its third fiscal quarter ended January 31, 2026. Revenue reached $24.6 million, up 63% from the prior-year period, driven by higher ASSURE system prescriptions, market share gains and a richer mix of in-network patients.
Gross margin improved to 52.6% from 43.4%, but GAAP net loss widened to $34.2 million from $21.8 million as operating expenses rose with commercial expansion and public company costs. Adjusted EBITDA loss was $21.2 million. Cash and cash equivalents were $291 million as of January 31, 2026, reflecting proceeds from a 6.9 million-share equity offering. The company raised its fiscal 2026 revenue guidance to $93 million, implying 55% growth versus fiscal 2025.
Positive
- Rapid top-line growth and guidance raise: Q3 FY26 revenue rose 63% year over year to $24.6 million, gross margin expanded to 52.6%, and fiscal 2026 revenue guidance increased to $93 million, implying 55% growth versus FY25.
- Strong liquidity position: Cash and cash equivalents totaled $291 million as of January 31, 2026, supported by an underwritten public offering of 6.9 million common shares completed in December 2025.
Negative
- Large and growing losses: Q3 GAAP net loss widened to $34.2 million from $21.8 million, and nine-month GAAP net loss reached $92.8 million with Adjusted EBITDA loss of $60.3 million, reflecting heavy operating spend.
- Rising operating expenses: GAAP operating expenses increased to $47.7 million in Q3 from $27.1 million a year earlier, even excluding non-recurring items and share-based compensation, highlighting the cost of accelerated commercial expansion.
Insights
Kestra is delivering rapid growth and margin expansion but remains deeply loss-making as it invests heavily in commercialization.
Kestra Medical Technologies posted Q3 fiscal 2026 revenue of $24.6 million, up 63% year over year, with 5,462 ASSURE prescriptions, up 58%. Gross margin expanded sharply to 52.6% from 43.4%, helped by scale, more in-network patients and cost initiatives.
Operating expenses climbed to $47.7 million from $27.1 million, reflecting accelerated commercial expansion, non-recurring costs of $1.5 million and higher share-based compensation. That pushed GAAP net loss to $34.2 million and Adjusted EBITDA loss to $21.2 million for the quarter.
Cash and cash equivalents of $291 million as of January 31 2026 were bolstered by an underwritten public offering of 6.9 million common shares closed on December 4 2025. Management lifted fiscal 2026 revenue guidance to $93 million, up from prior guidance of $91 million and initial $85 million, signaling continued confidence in demand for its wearable defibrillator platform.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: ( |
Not applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On March 17, 2026, Kestra Medical Technologies, Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended January 31, 2026. A copy of the press release, dated March 17, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press Release of Kestra Medical Technologies, Ltd., dated March 17, 2026 |
104 |
|
Cover Page Interactive Data File, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Kestra Medical Technologies, Ltd. |
|
|
|
|
|
Date: March 17, 2026 |
|
By: |
/s/ Brian Webster |
|
|
Name: |
Brian Webster |
|
|
Title: |
President and Chief Executive Officer |
Exhibit 99.1
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) – Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2026, which ended January 31, 2026.
Financial Highlights
“Kestra delivered another strong quarter of financial performance, generating revenue growth of 63% while expanding gross margin to over 52%,” said Brian Webster, President and CEO. “We also continued to execute on several key operational objectives, including rapid growth of the commercial organization, release of compelling primary results from our FDA post-approval study, fortification of our balance sheet with an equity offering, and entrance into a strategic collaboration with Biobeat Technologies. As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers.”
Third Quarter Fiscal 2026 Financial Results
*Adjusted EBITDA is a non-GAAP financial measure. See “Use of Non-GAAP Financial Measures” below for additional information. A reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure is included in this press release.
Fiscal Year 2026 Revenue Guidance
Kestra is increasing its FY26 revenue guidance to $93 million, which would represent growth of 55% compared to FY25. This compares to prior FY26 revenue guidance of $91 million and initial FY26 guidance of $85 million.
Webcast and Conference Call
Kestra will host a conference call today at 4:30 p.m. ET to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website.
Use of Non-GAAP Financial Measures
This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.
Adjusted EBITDA, which is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring expenses, is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate the Company’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.
The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.
Forward-Looking Statements
Except where otherwise noted, the information contained in this press release is as of March 17, 2026. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, the Company
undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2025 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.
About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.
Investorcontact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(unaudited)
|
|
Three Months Ended January 31, |
|
|
Nine Months Ended January 31, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenue |
|
$ |
24,552 |
|
|
$ |
15,090 |
|
|
$ |
66,488 |
|
|
$ |
42,582 |
|
Cost of revenue |
|
|
11,646 |
|
|
|
8,543 |
|
|
|
33,307 |
|
|
|
26,005 |
|
Gross profit |
|
|
12,906 |
|
|
|
6,547 |
|
|
|
33,181 |
|
|
|
16,577 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
4,972 |
|
|
|
3,353 |
|
|
|
13,850 |
|
|
|
10,266 |
|
Selling, general and administrative |
|
|
42,699 |
|
|
|
23,795 |
|
|
|
114,728 |
|
|
|
64,477 |
|
Total operating expenses |
|
|
47,671 |
|
|
|
27,148 |
|
|
|
128,578 |
|
|
|
74,743 |
|
Loss from operations |
|
|
(34,765 |
) |
|
|
(20,601 |
) |
|
|
(95,397 |
) |
|
|
(58,166 |
) |
Other expense (income): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
1,888 |
|
|
|
1,783 |
|
|
|
5,702 |
|
|
|
5,974 |
|
Interest income |
|
|
(2,163 |
) |
|
|
(628 |
) |
|
|
(6,125 |
) |
|
|
(1,543 |
) |
Other expense (income) |
|
|
(359 |
) |
|
|
(15 |
) |
|
|
(2,299 |
) |
|
|
73 |
|
Net loss before provision for income taxes |
|
|
(34,131 |
) |
|
|
(21,741 |
) |
|
|
(92,675 |
) |
|
|
(62,670 |
) |
Provision for income taxes |
|
|
35 |
|
|
|
18 |
|
|
|
102 |
|
|
|
33 |
|
Net loss and comprehensive loss |
|
|
(34,166 |
) |
|
|
(21,759 |
) |
|
|
(92,777 |
) |
|
|
(62,703 |
) |
Net loss attributable to non-controlling interest |
|
|
— |
|
|
|
(250 |
) |
|
|
— |
|
|
|
(942 |
) |
Net loss and comprehensive loss attributable to Kestra Medical Technologies, Ltd. |
|
|
(34,166 |
) |
|
|
(21,509 |
) |
|
|
(92,777 |
) |
|
|
(61,761 |
) |
Less: Undeclared preferred stock dividends |
|
|
— |
|
|
|
3,324 |
|
|
|
— |
|
|
|
9,030 |
|
Net loss attributable to common shareholders, basic and diluted |
|
$ |
(34,166 |
) |
|
$ |
(24,833 |
) |
|
$ |
(92,777 |
) |
|
$ |
(70,791 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share attributable to common shareholders, basic and diluted |
|
$ |
(0.61 |
) |
|
$ |
(1.25 |
) |
|
$ |
(1.76 |
) |
|
$ |
(3.56 |
) |
Weighted-average shares of common shares outstanding, basic and diluted |
|
|
55,848,413 |
|
|
|
19,885,382 |
|
|
|
52,843,097 |
|
|
|
19,885,382 |
|
RECONCILIATION OF GAAP NET LOSS AND COMPREHENSIVE LOSS TO ADJUSTED EBITDA
(in thousands)
(unaudited)
|
|
Three Months Ended January 31, |
|
|
Nine Months Ended January 31, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP Net loss and comprehensive loss |
|
$ |
(34,166 |
) |
|
$ |
(21,759 |
) |
|
$ |
(92,777 |
) |
|
$ |
(62,703 |
) |
Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
1,888 |
|
|
|
1,783 |
|
|
|
5,702 |
|
|
|
5,974 |
|
Interest income |
|
|
(2,163 |
) |
|
|
(628 |
) |
|
|
(6,125 |
) |
|
|
(1,543 |
) |
Other expense (income) |
|
|
(359 |
) |
|
|
(15 |
) |
|
|
(2,299 |
) |
|
|
73 |
|
Provision for income taxes |
|
|
35 |
|
|
|
18 |
|
|
|
102 |
|
|
|
33 |
|
Depreciation expense |
|
|
1,984 |
|
|
|
1,888 |
|
|
|
6,384 |
|
|
|
6,132 |
|
Share-based compensation expense |
|
|
10,108 |
|
|
|
459 |
|
|
|
23,340 |
|
|
|
1,958 |
|
Non-recurring expenses |
|
|
1,482 |
|
|
|
1,927 |
|
|
|
5,396 |
|
|
|
1,927 |
|
Adjusted EBITDA |
|
$ |
(21,191 |
) |
|
$ |
(16,327 |
) |
|
$ |
(60,277 |
) |
|
$ |
(48,149 |
) |
KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(unaudited)
|
|
January 31, |
|
|
April 30, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
|
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
291,321 |
|
|
$ |
237,595 |
|
Accounts receivable, net |
|
|
12,709 |
|
|
|
8,081 |
|
Disposable medical equipment supplies |
|
|
6,829 |
|
|
|
6,572 |
|
Prepaid expenses and other current assets |
|
|
3,204 |
|
|
|
3,080 |
|
Total current assets |
|
|
314,063 |
|
|
|
255,328 |
|
|
|
|
|
|
|
|
||
Right-of-use assets |
|
|
3,419 |
|
|
|
2,078 |
|
Deposits |
|
|
1,847 |
|
|
|
2,021 |
|
Restricted cash |
|
|
334 |
|
|
|
334 |
|
Property and equipment, net |
|
|
53,799 |
|
|
|
34,830 |
|
Other long-term assets |
|
|
5,880 |
|
|
|
1,153 |
|
Total assets |
|
$ |
379,342 |
|
|
$ |
295,744 |
|
|
|
|
|
|
|
|
||
Liabilities and Shareholders’ Equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
24,023 |
|
|
$ |
23,961 |
|
Accrued liabilities |
|
|
18,898 |
|
|
|
13,829 |
|
Operating lease liabilities, current portion |
|
|
10 |
|
|
|
187 |
|
Total current liabilities |
|
|
42,931 |
|
|
|
37,977 |
|
|
|
|
|
|
|
|
||
Operating lease liabilities, net of current portion |
|
|
4,276 |
|
|
|
3,026 |
|
Warrant liabilities |
|
|
1,745 |
|
|
|
8,097 |
|
Other long-term liabilities |
|
|
140 |
|
|
|
140 |
|
Long-term debt, net |
|
|
42,261 |
|
|
|
41,098 |
|
Total liabilities |
|
|
91,353 |
|
|
|
90,338 |
|
|
|
|
|
|
|
|
||
Commitments and contingencies |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Shareholders’ equity |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Common Shares, $1.00 par value; 100,000,000 shares authorized as of January 31, 2026 and April 30, 2025; 58,349,053 issued and outstanding as of January 31, 2026 and 51,348,656 shares issued and outstanding as of April 30, 2025 |
|
|
58,349 |
|
|
|
51,349 |
|
Additional paid-in capital |
|
|
842,666 |
|
|
|
674,306 |
|
Accumulated deficit |
|
|
(613,026 |
) |
|
|
(520,249 |
) |
Total shareholders’ equity |
|
|
287,989 |
|
|
|
205,406 |
|
Total liabilities and shareholders’ equity |
|
$ |
379,342 |
|
|
$ |
295,744 |
|
KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
|
|
Nine Months Ended January 31, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
(92,777 |
) |
|
$ |
(62,703 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
6,384 |
|
|
|
6,132 |
|
Loss on disposal of property and equipment |
|
|
727 |
|
|
|
882 |
|
Reserve for lost equipment and supplies |
|
|
1,600 |
|
|
|
647 |
|
Provision for uncollectible accounts receivable |
|
|
1,515 |
|
|
|
1,883 |
|
Interest paid-in-kind |
|
|
— |
|
|
|
703 |
|
Amortization of debt discounts and issuance costs |
|
|
1,406 |
|
|
|
1,031 |
|
Share-based compensation expense |
|
|
23,340 |
|
|
|
1,958 |
|
Non-cash lease expense |
|
|
273 |
|
|
|
330 |
|
Change in fair value of warrant liabilities |
|
|
(2,297 |
) |
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Disposable medical equipment supplies |
|
|
(466 |
) |
|
|
(2,823 |
) |
Prepaid expenses and other current assets |
|
|
421 |
|
|
|
(431 |
) |
Accounts receivable |
|
|
(6,143 |
) |
|
|
(7,814 |
) |
Accounts payable |
|
|
(647 |
) |
|
|
3,665 |
|
Accrued liabilities |
|
|
4,192 |
|
|
|
2,730 |
|
Operating lease liabilities |
|
|
(541 |
) |
|
|
228 |
|
Other long-term assets |
|
|
30 |
|
|
|
30 |
|
Net cash used in operating activities |
|
|
(62,983 |
) |
|
|
(53,552 |
) |
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
(25,228 |
) |
|
|
(15,547 |
) |
Deposits for medical rental equipment |
|
|
(527 |
) |
|
|
(627 |
) |
Refund of deposits for medical rental equipment |
|
|
184 |
|
|
|
270 |
|
Investment in equity security |
|
|
(5,000 |
) |
|
|
— |
|
Net cash used in investing activities |
|
|
(30,571 |
) |
|
|
(15,904 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
||
Proceeds from issuance of common stock |
|
|
149,291 |
|
|
|
— |
|
Payment of equity issuance costs |
|
|
(1,986 |
) |
|
|
(3,293 |
) |
Deemed dividend for payments to third party on behalf of shareholder |
|
|
(25 |
) |
|
|
(1,648 |
) |
Proceeds from issuance of redeemable preferred stock |
|
|
— |
|
|
|
103,400 |
|
Proceeds from issuance of stock to non-controlling interest |
|
|
— |
|
|
|
17,100 |
|
Net cash provided by financing activities |
|
|
147,280 |
|
|
|
115,559 |
|
Net increase in cash, cash equivalents and restricted cash |
|
|
53,726 |
|
|
|
46,103 |
|
Cash, cash equivalents and restricted cash |
|
|
|
|
|
|
||
Beginning of period |
|
|
237,929 |
|
|
|
8,583 |
|
End of period |
|
$ |
291,655 |
|
|
$ |
54,686 |
|
FAQ
How did Kestra Medical Technologies (KMTS) perform in Q3 fiscal 2026?
What were Kestra Medical Technologies’ profitability and margin trends in Q3 FY26?
What revenue guidance did Kestra Medical Technologies (KMTS) provide for fiscal 2026?
What is Kestra Medical Technologies’ cash position and recent financing activity?
How fast are Kestra Medical Technologies’ operating expenses growing?
What non-GAAP metric does Kestra Medical Technologies highlight and why?
Filing Exhibits & Attachments
2 documentsPress Releases
